Avidity Biosciences Inc RNA

NAS: RNA | ISIN: US05370A1088   14/11/2024
49,97 USD (-4,82%)
(-4,82%)   14/11/2024

5 september 2024 · Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month · Persbericht

28 augustus 2024 · Avidity Biosciences to Participate in Upcoming Investor Conferences · Persbericht

21 augustus 2024 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

19 augustus 2024 · Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares · Persbericht

15 augustus 2024 · Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock · Persbericht

13 augustus 2024 · Avidity Biosciences Announces Proposed Public Offering of Common Stock · Persbericht

9 augustus 2024 · Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights · Persbericht

9 augustus 2024 · Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in the Phase 1/2 EXPLORE44™ Trial · Persbericht

5 augustus 2024 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

5 augustus 2024 · Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer · Persbericht

22 juli 2024 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

21 juni 2024 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

20 juni 2024 · Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day · Persbericht

17 juni 2024 · Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares · Persbericht

14 juni 2024 · Avidity Biosciences to Participate in Upcoming Investor Conference · Persbericht

14 juni 2024 · Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock · Persbericht

12 juni 2024 · Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock · Persbericht

12 juni 2024 · Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy · Persbericht

29 mei 2024 · Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress · Persbericht

21 mei 2024 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

Mijn selecties